Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M London

Showing results (541-550 of 559) with videos related to

Pageof 56
Sort By:
Journal of the American Society of Nephrology : JASN|December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE TrialSharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
Journal of Human Hypertension|June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trialT I Chang, S Abdalla, G M London, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.
Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trialPatrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 21, 2014
Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)Iain C Macdougall, Nicole Casadevall, Francesco Locatelli, et al.
Pageof 56

Showing results (541-550 of 559) with videos related to

Sort By:
Pageof 56
Journal of the American Society of Nephrology : JASN|December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE TrialSharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
Journal of Human Hypertension|June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trialT I Chang, S Abdalla, G M London, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.
Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trialPatrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 21, 2014
Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)Iain C Macdougall, Nicole Casadevall, Francesco Locatelli, et al.
Pageof 56